Current therapeutic anticoagulation with warfarin (or coumarin derivatives)
Patients for whom prophylactic anticoagulation therapy (eg. 81 or 325 mg aspirin PO daily or warfarin (Coumadin) 1-2 mg/day, or any other coumarin-derivative anticoagulants) is not an option unless due to thrombocytopenia
Those who require therapeutic anticoagulation with coumarin-derivative anticoagulants
Current therapeutic anticoagulation with warfarin (or coumarin derivatives)
Known coagulopathies, and those who require therapeutic anticoagulation with coumarin-derivative anticoagulants
Patients who are currently receiving treatment with warfarin sodium (Coumadin®) or any other coumarin-derivative anti-coagulants
Therapeutic treatment with Coumadin or any other coumarin-derivative anticoagulant
Patients for whom prophylactic anticoagulation therapy (eg. 325mg aspirin PO daily or warfarin [Coumadin] 1-2 mg/day, or any other coumarin-derivative anticoagulants) is not an option
Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed
Patients receiving anticoagulation therapy with Coumadin are not eligible for study; (patients on non-coumadin anticoagulants [Lovenox, Xarelto, etc.] are eligible for study; patients on Coumadin who can be transitioned to Lovenox prior to starting study treatments will be eligible)
Ongoing treatment with Coumadin.
Current treatment with therapeutic doses of Coumadin-derivative anticoagulants (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed)
Inability to stop antiplatelet and Coumadin therapy for 7 days prior to and 7 days post treatment with the NanoKnife system
Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes\r\n* Strong inhibitors or strong inducers of CYP3A4/5, and medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, and/or CYP2C9\r\n* Therapeutic doses of warfarin sodium (coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids in the 5 days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents
Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of CYP3A4/5\r\n* Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, and/or CYP2C9\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-­derived anti­coagulant\r\n* Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids? If patients are on corticosteroids for endocrine deficiencies or tumor­-associated symptoms, dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.
Patients who are currently taking Coumadin or Coumadin derivatives
Current use of therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulants; heparin and/or low molecular weight heparins or other anticoagulants are allowed
CERITINIB EXCLUSION CRITERIA: Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with study drug and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of CYP3A4/5\r\n* Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, and/or CYP2C9\r\n* Therapeutic doses of warfarin sodium (coumadin) or any other coumadin-derived anticoagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Patients on Coumadin must be changed to Lovenox at least 1 week prior to starting capecitabine; low dose (1 mg) Coumadin is allowed; intravenous and low-molecular weight heparin are permitted
Patients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
Patients taking Coumadin, other agents containing warfarin, rivaroxaban, or dabigatran; (exception: low dose Coumadin [1 mg or less daily] administered prophylactically for maintenance of in-dwelling lines or ports is allowed)
Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant
Patients who require coumadin administration.
Use of anti-coagulants such as coumadin, heparin, or Lovenox within 14 days before treatment
Patients who cannot discontinue Plavix, Coumadin or other anti-platelet or anti-coagulant medications
Current use of warfarin sodium or any other coumadin-derivative anticoagulant; participant must be off coumadin-derivative anticoagulants for at least 7 days prior to planned start of study treatment; low molecular weight heparin and factor Xa inhibitors are allowed
Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists
Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines.
Patients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
Current use of warfarin sodium or any other coumadin-derivative anticoagulant; participants must be off coumadin-derivative anticoagulants for at least 7 days prior to starting study drug; low molecular weight heparin is allowed
Full anti-coagulant therapy Coumadin; patients may be receiving therapeutic Lovenox, Fragmin, or other heparin product that does not require laboratory monitoring
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant are ineligible
Low-dose Coumadin (1 mg) is acceptable; however, doses that increase INR are not permitted; if an alternative to Coumadin-based anticoagulants cannot be used, the INR should be monitored weekly after initiation of therapy and upon discontinuation of INCB024360, until INR normalization
Low-dose Coumadin (1 mg) is acceptable; however, doses that increase INR are not permitted; if an alternative to Coumadin-based anticoagulants cannot be used, the INR should be monitored weekly after initiation of therapy and upon discontinuation of INCB024360, until INR normalization
Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant
Patients receiving warfarin (Coumadin®)
Patients receiving Coumadin
Patients who are taking Coumadin or Coumadin derivatives.
Treatment with Coumadin; patients who recently received Coumadin must be off Coumadin for at least 7 days prior to start of the study
Current therapeutic anticoagulation with Coumadin (warfarin)
Patient is using warfarin or any other Coumadin-derivative anticoagulant; patients must be off Coumadin-derivative anticoagulants for at least seven days prior to starting the study drug; low molecular weight heparin is allowed
Patients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant
Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant; patients who can be safely changed to enoxaparin or other non-warfarin derived anti-coagulant and who otherwise meet eligibility requirements may be enrolled
Participants requiring the use of therapeutic doses of warfarin (Coumadin)
Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed
Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant
Patient is receiving warfarin (Coumadin)
Treatment with Coumadin® or other anti-coagulant therapy (except aspirin) < 4 weeks prior to enrollment
Patients with an active bleeding tendency or are receiving any treatment with therapeutic doses of sodium warfarin (Coumadin) or coumadin derivatives; patients will be allowed to enter study on aspirin doses of 81 mg/d
Patients who require therapeutic doses of Coumadin derivative anticoagulants such as warfarin are excluded; low molecular weight heparin is permitted, provided the patient’s PT/INR is =< 1.5; Coumadin doses of up to 2 mg daily are permitted for prophylaxis of thrombosis
Active bleeding diathesis or current treatment with therapeutic doses of sodium warfarin (Coumadin) or other vitamin K active agents (Note: mini-dose of Coumadin (e.g., 1 mg/day) or anti-coagulants given to maintain intravenous line patency, as well as unfractionated or low molecular weight heparin therapy are permitted)
Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin) are ineligible
Patients who are currently taking Coumadin are not eligible
Patients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant; low molecular weight heparin is allowed
Ongoing anticoagulant therapy (eg, aspirin, coumadin, heparin).
Ongoing anticoagulant therapy (eg, aspirin, coumadin, heparin).
Currently receiving warfarin or other coumadin-derived anticoagulants for treatment, prophylaxis or otherwise.
Patients who require treatment with therapeutic doses of coumadin-type anticoagulants (maximum daily dose of 1mg allowed for port line patency permitted).
Patient must not be on full dose Coumadin
Patients with thromboembolic disease cannot be on Coumadin, but low molecular heparins are allowed
Subjects receiving Coumadin anticoagulants
No concurrent warfarin or Coumadin-derivatives
Patients on therapeutic doses of Coumadin or Lovenox are ineligible to participate in study
Current treatment with warfarin sodium or any other Coumadin-derivative anticoagulant
Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant
Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a significant known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of cytochrome P450 family 3, subfamily A, polypeptide 4/5 (CYP3A4/5)\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Use of Coumadin (warfarin) or other vitamin-K antagonists for anticoagulation; non-Coumadin anticoagulation is permitted
Use of full anticoagulant doses of coumadin or heparin (exception: 1 mg/day of coumadin for preventing catheter clots is allowed)
Use of anticoagulant agent (warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, or Warfant)
Concomitant treatment with full dose warfarin (coumadin) is NOT allowed; however, treatment with low molecular weight heparin (LMWH) (such as enoxaparin or dalteparin) or rivaroxaban is allowed; patients on full dose warfarin (coumadin) must be transitioned to either LMWH or rivaroxaban prior to administration of any study related drugs
Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists; patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug; low molecular weight heparin is allowed; patients with congenital bleeding diathesis are excluded
Participant is currently receiving treatment with anticoagulants (e.g. Coumadin)
No concurrent full dose anticoagulant therapy; =< 1 mg/day of Coumadin for preventing catheter clots allowed
Patients taking Coumadin, Pradaxa or other blood thinner drugs
Use of Coumadin or acenocoumarol at time of screening
Women on Coumadin, Xarelto, or other anticoagulants
Currently prescribed anti-coagulation medications (ReoPro [abciximab], Aggrenox [aspirin plus dipryridamole], Persantine [dipyridamole], Integrillin [eptifibatide], Ticlid [ticlopidine], Aggrastat [terofiban], Heparin, Coumadin [warfarin], Pradaxa [dabigatran], Xarelto [rivaroxaban])
Use of anticoagulation medications, including but not limited to coumadin, warfarin, plavix
Use of any anticoagulation medications, such as warfarin or Coumadin
Subjects on Coumadin or other anticoagulants
Concurrent use of anticoagulants (i.e. Coumadin/warfarin)
Any consumption of prescription anticoagulants, including Coumadin and Lovenox, during the 3 weeks prior to baseline RPFNA
History of a bleeding tendency or current use of Coumadin or other anticoagulants
Patients on blood thinners (aspirin or Coumadin) will be asked to stop medications 7 days prior to surgery; in the case of Coumadin, patients are switched to Lovenox 7 days prior to surgery and this is stopped the day before surgery; following surgery aspirin or Coumadin are recommenced 48 hours post operation (postop)
Ongoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel, coumadin, heparin, or warfarin) that cannot be held to permit tumor biopsy).
